Clinical Trials on Leukemia, Lymphoblastic, Acute

Total 18673 results

National University of Malaysia
Gaia Science

Recruiting

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Relapsed B Acute Lymphoblastic Leukaemia | Refractory B Acute Lymphoblastic Leukaemia

Malaysia
ECOG-ACRIN Cancer Research Group

Recruiting

Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTD

Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia Recurrent

China
Institut Paoli-Calmettes
INATHERYS

Recruiting

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03)

Acute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia Recurrent

France
St. Anna Kinderkrebsforschung
Assistance Publique - Hôpitaux de Paris; Australian & New Zealand Children's... and other collaborators

Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia

Italy, Israel, Spain, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, Croatia, Czechia, Denmark, Finland, Greece, Malaysia, Mexico, Netherlands, Norway, Poland, Romania, Saudi Arabia, Slovakia, Sweden, Switzerland, Turkey, F... and more
medac GmbH

Terminated

Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia

Germany
University College, London
Cancer Research UK; Stichting Hemato-Oncologie voor Volwassenen Nederland

Completed

A Study for Older Adults With Acute Lymphoblastic Leukaemia (UKALL60+)

Acute Lymphoblastic Leukaemia

United Kingdom, Netherlands
Aarhus University Hospital

Unknown

A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia

Denmark
Sanofi

Terminated

SAR3419 in Acute Lymphoblastic Leukemia (MYRALL)

Acute Lymphocytic Leukaemia

United States, France
National Cancer Institute (NCI)

Completed

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...

United States
Autolus Limited

Completed

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)

Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic Leukemia

United Kingdom
Mundipharma Research Limited
Innovative Therapies For Children with Cancer Consortium

Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)

Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's Lymphoma

Czech Republic, Austria, France, Germany, Italy, United Kingdom
GlaxoSmithKline

Completed

Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma

Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic

Japan
Children's Oncology Group
National Cancer Institute (NCI); ImmunoGen, Inc.

Withdrawn

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
University of Birmingham
AstraZeneca; Cancer Research UK

Terminated

International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia Recurrent

United Kingdom, Denmark, Netherlands
GlaxoSmithKline

Completed

Observational Study of Nelarabine in Children and Young Adults

Leukaemia, Lymphoblastic, Acute

Russian Federation, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Spain
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Childhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia
University College, London

Recruiting

Determining the Mechanisms of Loss of CAR T Cell Persistence (CARPERS)

Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United Kingdom
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Therapeutic Advances in Childhood Leukemia Consortium
Enzon Pharmaceuticals, Inc.

Terminated

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Lymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T Cell

United States, Australia
Cedars-Sinai Medical Center
Amgen

Active, not recruiting

Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

B-ALL | B-Cell Acute Lymphoblastic Leukaemia | ALL, Adult

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia | Adult Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia

United States
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, Switzerland
St. Petersburg State Pavlov Medical University

Completed

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Acute Myeloid Leukemia | Leukemia, Acute Lymphoblastic | Mixed-Lineage Acute Leukemias

Russian Federation
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States, Canada, Australia, Puerto Rico
Beijing Boren Hospital

Recruiting

Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Beijing GoBroad Hospital

Recruiting

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Leukemia

China
Tanja Andrea Gruber

Recruiting

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Acute Lymphoblastic Leukemia, Pediatric | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia

United States
Sanofi

Terminated

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)

T-cell Type Acute Leukemia-Precursor | T-lymphoblastic Lymphoma/Leukaemia

Hungary, United States, Finland, France, Italy, Lithuania, Russian Federation
Asan Medical Center

Terminated

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Lymphoblastic Lymphoma | Leukemia, Biphenotypic, Acute | Leukemia, Acute Lymphoblastic | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Precursor B-Cell Lymphoblastic Leukemia

Korea, Republic of
Syndax Pharmaceuticals

Active, not recruiting

A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
Stanford University
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia (ALL) | Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) | Recurrent Adult Acute Lymphoblastic Leukemia (ALL) | T-cell Adult Acute Lymphoblastic Leukemia (ALL)

United States
National Cancer Institute (NCI)

Active, not recruiting

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic Leukemia

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand
University of Minnesota
Children's Cancer Research Fund United States

Terminated

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

Lymphoblastic Lymphoma | Brain Tumors | Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Leukemia, Lymphocytic, Acute | Leukemia, Lymphoblastic, Acute | Brain Neoplasms, Malignant | ALL, Childhood | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Lymphoblastic Leukemia, Acute | Leukemia... and other conditions

United States
M.D. Anderson Cancer Center

Withdrawn

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Acute Myeloid Leukemia (AML) | Refractory T Acute Lymphoblastic Leukemia

United States
Children's Oncology Group

Recruiting

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Lymphoblastic Lymphoma | B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

United States, Canada
Northwestern University
National Cancer Institute (NCI)

Terminated

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 | Refractory Childhood Acute Lymphoblastic Leukemia

United States

Clinical Trials on Leukemia, Lymphoblastic, Acute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations